TY  - GEN
AU  - Levy,Benjamin
AU  - Paz-Ares,Luis
AU  - Bennouna,Jaafar
AU  - Felip,Enriqueta
AU  - Abreu,Delvys Rodríguez
AU  - Isla,Dolores
AU  - Barlesi,Fabrice
AU  - Molinier,Olivier
AU  - Madelaine,Jeannick
AU  - Audigier-Valette,Clarisse
AU  - Kim,Sang-We
AU  - Kim,Hye Ryun
AU  - Ozguroglu,Mustafa
AU  - Erman,Mustafa
AU  - Badin,Firas Benyamine
AU  - Mekhail,Tarek M
AU  - Scheff,Ronald
AU  - Chisamore,Michael J
AU  - Sadrolhefazi,Behbood
AU  - Riess,Jonathan W
TI  - Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol
SN  - 1938-0690
PY  - 2020///0403
KW  - Female
KW  - Humans
KW  - Male
KW  - Afatinib
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Squamous Cell
KW  - drug therapy
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Immunotherapy
KW  - methods
KW  - Lung Neoplasms
KW  - Mutation
KW  - genetics
KW  - Neoplasm Staging
KW  - Programmed Cell Death 1 Receptor
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Clinical Trials, Phase II as Topic
N1  - Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.cllc.2018.12.022
ER  -